Director
AbbVie Inc.
Gregory Calip is an experienced cancer epidemiologist with over a decade of experience in academia and the healthtech industry. After completing his PharmD and MPH in Biostatistics, he received his PhD in Epidemiology from the University of Washington and completed postdoctoral training at the Fred Hutchinson Cancer Center in Seattle. He was previously Associate Professor at the University of Illinois Chicago in the Center for Pharmacoepidemiology and Pharmacoeconomic Research where his NIH-funded research focused primarily on health inequities in multiple myeloma and cancer treatment-related cardiotoxicity. More recently, at Flatiron Health, Greg was Quantitative Sciences Head of Academic Health Systems and Principal Quantitative Scientist in the Flatiron Health Research Unit, where he conducted research focused on the impacts of COVID-19 on oncology real-world evidence, propensity score calibration methods for missing data, and the representativeness of oncology clinical trials. Greg is currently Director of Global Epidemiology (Oncology) at AbbVie and adjunct faculty at the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences in the Program on Medicines and Public Health.